Search
Regenxbio Inc
RGNXAdd to Watchlist
7.895USD
+0.965+13.92%
Close 06/17, 16:00（ET）Quotes delayed by 15 min
407.52MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-16The current earnings forecast score of Regenxbio Inc is 8.46, ranking 121 out of 388 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 52.00 and a low of 14.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
25.750
Target Price
+271.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Regenxbio Inc
RGNX
13
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Regenxbio Inc's expected revenue for the next quarter?
Regenxbio Inc's expected revenue is 119.09M.
What is Regenxbio Inc's price target?
Analysts forecast that Regenxbio Inc's price target is USD 34.00, with the highest forecast at USD 52.00 and the lowest forecast at USD 14.00.
How have Regenxbio IncRGNX's recent earnings per share performed?
The market expectation was USD -1.72, while Regenxbio IncRGNX's earnings per share (EPS) for the previous quarter was USD -1.30. EPS for the next quarter is expected at USD 0.22.
What is the analyst rating for Regenxbio Inc?
Based on the ratings of Regenxbio Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
